We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $155.06, moving +1.33% from the previous trading session. This change outpaced the S&P 500's 1.1% gain on the day. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, added 1.35%.
Coming into today, shares of the kidney dialysis provider had lost 8.37% in the past month. In that same time, the Medical sector lost 3.78%, while the S&P 500 gained 0.22%.
Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. The company is predicted to post an EPS of $2.21, indicating a 18.18% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $3.25 billion, up 3.47% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $9.71 per share and revenue of $12.8 billion. These totals would mark changes of +14.64% and +5.45%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 15.76. This expresses a discount compared to the average Forward P/E of 21.96 of its industry.
It's also important to note that DVA currently trades at a PEG ratio of 0.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 2.04.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $155.06, moving +1.33% from the previous trading session. This change outpaced the S&P 500's 1.1% gain on the day. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, added 1.35%.
Coming into today, shares of the kidney dialysis provider had lost 8.37% in the past month. In that same time, the Medical sector lost 3.78%, while the S&P 500 gained 0.22%.
Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. The company is predicted to post an EPS of $2.21, indicating a 18.18% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $3.25 billion, up 3.47% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $9.71 per share and revenue of $12.8 billion. These totals would mark changes of +14.64% and +5.45%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 15.76. This expresses a discount compared to the average Forward P/E of 21.96 of its industry.
It's also important to note that DVA currently trades at a PEG ratio of 0.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 2.04.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.